WELCOME TO ADAPTVAC
AdaptVac aims to accelerate the development of safe and efficacious therapeutic and prophylactic vaccines to treat and prevent specific cancers, infectious diseases and immunological disorders.
AdaptVac is currently focused on developing a COVID-19 vaccine
COVID-19 VACCINE DEVELOPMENT
AdaptVac, as part of the EU H2020 funded PREVENT-nCoV consortium, is focused on developing a SARS-CoV-2 (COVID-19) vaccine using our capsid Virus-Like Particle (VLP) display technology.
WHO WE ARE
AdaptVac is a joint-venture between NASDAQ First North listed ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines.
The goal of the Joint Venture is to create a world class unit for the development of highly competitive vaccines and therapeutics against infectious diseases, cancer, and immunological disorders. The combination of ExpreS2ion’s proprietary insect cell expression technology, ExpreS2, and NextGen’s unique expertise in proprietary Virus-Like Particle (VLP) technology makes us a strong and versatile player in the field of new vaccines and immune therapy.
VIRUS-LIKE PARTICLE DISPLAY TECHNOLOGY
Virus-like particles (VLPs) represent a significant advance in the development of subunit vaccines, combining high safety and efficacy. Their particulate nature and dense repetitive subunit organisation makes them ideal scaffolds for display of vaccine antigens. Traditional approaches for VLP-based antigen display require labor-intensive trial-and-error optimisation, and often fail to generate dense antigen display. Here we utilise the split-protein conjugation system to generate stable isopeptide bound antigen-VLP complexes by simply mixing of the antigen and VLP components.
AdaptVac has an open approach to our VLP display technology and welcomes collaborations with leading research groups and companies to advance innovative vaccines and immunotherapies.